Two additional studies utilized GFAP and Iba1 expression to evaluate if a mitogen-activated protein kinase or a monoacylglycerol lipase inhibitor alters ALS pathology (Fujisawa et al., 2016; Pasquarelli et al., 2017). The gene discussed is GFAP; the disease is amyotrophic lateral sclerosis.